Pangea Bio dosed the first participants in the Phase 1 first-in-human study of OT-003, a small molecule that positively modulates TrkB itself.
Public source
Publisher name
Public post
Pangea Bio dosed the first participants in the Phase 1 first-in-human study of OT-003 — our lead #TrkB positive allosteric modulator. Nearly a decade ago, I was fortunat…
Company
Pangea Bio
Novel Therapies for Central Nervous System Disorders
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 11–50 employees
About Pangea Bio
Pangea Bio is developing novel therapies that directly activate the TrkB receptor, driving neuronal and synaptic plasticity, and neuroprotection. Dysfunction of the BDNF/TrkB pathway is a hallmark of disorders such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, and glaucoma.
See moreLatest activity
Latest activity from Pangea Bio
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Newron Pharmaceuticals SpA
Newron Pharmaceuticals SpA completed the screening for enrollment for the pivotal Phase III ENIGMA-TRS 1 program, an international, double-blind, randomized, placebo-controlled, one-year trial evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia.
Research & Knowledge
Baseimmune
Baseimmune reported 74 patients with prodromal Alzheimer's disease dosed across 3 cohorts in a Phase 1b/2 trial of ACI-24.
Research & Knowledge
Clearmind Medicine
Clearmind Medicine reached a key milestone with the CMND-100 Phase IIa underway for an Alcohol Use Disorder Trial, with one-third of Part C enrolled.
Research & Knowledge
Alzamend Neuro
Alzamend Neuro announced that its most advanced product candidate AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate.
Research & Knowledge
Cerevance